How close are we to a pharmacogenomic test for clozapine-induced agranulocytosis?

Pharmacogenomics. 2015;16(9):915-7. doi: 10.2217/pgs.15.67. Epub 2015 Jun 30.

Authors

Moira Verbelen¹, Cathryn M Lewis^{1

2}

Affiliations

¹ MRC SGDP Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, Denmark Hill, London, SE5 8AF, UK.
² Department of Medical & Molecular Genetics, King's College London, 8th Floor Tower Wing, Guy's Hospital, Great Maze Pond, London, SE1 9RT, UK.

PMID: 26122865
DOI: 10.2217/pgs.15.67

No abstract available

Keywords: HLA; agranulocytosis; clozapine; pharmacogenomic testing.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Agranulocytosis / chemically induced*
Agranulocytosis / genetics*
Antipsychotic Agents / adverse effects*
Clozapine / adverse effects*
Genetic Testing
HLA Antigens / genetics
Humans
Pharmacogenetics

Substances

Antipsychotic Agents
HLA Antigens
Clozapine

Grants and funding

Medical Research Council/United Kingdom